As the heir to how to identify the best biotech companies for investment a rich history of farming and pharmaceutical drug breakthroughs, biotechnology has a big promise: drugs that take care of diseases, stop them, or cure all of them; new causes of energy just like ethanol; and upgraded crops and foods. In addition, its technologies are helping address the world’s environmental and social challenges.
Despite this legacy of success, the industry looks many conflicts. A major purpose is that general public equity market segments are badly designed for enterprises whose return and profits rely entirely upon long-term research projects that can take several years to carry out and may deliver either historic breakthroughs or utter failures. Meanwhile, the industry’s fragmented structure with scores of small , specialized players across far-flung disciplines impedes the posting and integration of important knowledge. Finally, the program for making money with intellectual residence gives specific firms a motivation to lock up valuable scientific knowledge instead of share this openly. It has led to nasty disputes over research and development, including the one among Genentech and Lilly above their recombinant human growth hormone or Amgen and Johnson & Johnson more than their erythropoietin drug.
But the industry is evolving. The various tools of finding have become far more diverse than in the past, with genomics, combinatorial biochemistry and biology, high-throughput screening process, and All of it offering in order to explore fresh frontiers. Tactics are also simply being developed to tackle “undruggable” proteins and also to target disease targets in whose biology can be not very well understood. The battle now is to integrate these improvements across the array of scientific, specialized, and practical websites.